No Data
Hunan Er-Kang Pharmaceutical (SZSE:300267 Shareholders Incur Further Losses as Stock Declines 6.6% This Week, Taking Five-year Losses to 55%
Erkang Pharmaceuticals: Report for the third quarter of 2024
hunan er-kang pharmaceutical (300267.SZ): a net loss of 31.7675 million yuan in the third quarter.
On October 24, Gelonhui reported that Hunan Er-Kang Pharmaceutical (300267.SZ) achieved revenue of 0.233 billion yuan in the third quarter of 2024, a year-on-year decrease of 41.06%; net income attributable to shareholders of the listed company was -31.7675 million yuan; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -34.3959 million yuan; basic earnings per share was -0.0154 yuan.
Concept Gold Rush | A major breakthrough in the "longevity medicine" concept, will concept stocks usher in an explosive period?
Increase by 100 times.
hunan er-kang pharmaceutical (300267.SZ): the construction work of the first selected mine in Nigeria has been basically completed
Gelonghui October 11th | Hunan Er-Kang Pharmaceutical (300267.SZ) recently stated at the performance briefing that the construction of the company's first ore dressing plant investment in Nigeria is basically completed, and currently accelerating equipment debugging work, striving to produce products as soon as possible.
Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) Market Cap Increased by CN¥371m, Insiders Receive a 45% Cut
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
No Data
